<DOC>
<DOCNO>EP-0646126</DOCNO> 
<TEXT>
<INVENTION-TITLE>
NOVEL STEROIDS WITH PREGNANE SKELETON, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3157	A61K3157	A61K3158	A61P300	A61P306	C07D23900	C07D23942	C07D23948	C07D23950	C07D49100	C07D49110	C07J900	C07J4300	C07J4300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07J	C07J	C07J	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61P3	A61P3	C07D239	C07D239	C07D239	C07D239	C07D491	C07D491	C07J9	C07J43	C07J43	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to novel, therapeutically active 21-aminosteroids of formula (I) with pregnane skeleton, wherein two of X, Y and Z mean a nitrogen atom each and the third one is a methine group; R
<
1
>
 and R
<
2
>
 represent, independently from each other, a primary amino group bearing as substituent a branched-chain C4-8alkyl, -alkenyl or -alkynyl group, or a C4-10cycloalkyl group comprising 1 to 3 ring(s) and being optionally substituted by C1-3alkyl group(s); or R
<
1
>
 and R
<
2
>
 stand together for a spiro-heterocyclic secondary amino group containing at most 10 carbon atoms and optionally at least one oxygen atom as additional heteroatom; or one of R
<
1
>
 and R
<
2
>
 means an unsubstituted heterocyclic secondary amino group containing 4 to 7 carbon atoms and the other one is an above-identified primary amino group, an above-identified spiro-heterocyclic secondary amino group, or a heterocyclic secondary amino group containing 4 to 7 carbon atoms and substituted by C1-4alkyl group(s); and n is 1 or 2, as well as their acid addition salts and pharmaceutical compositions containing these compounds. Furthermore, the invention relates to a process for the preparation of the above compounds. The compounds of formula (I) possess antioxidant, particularly lipid peroxidation-inhibiting effect, and therefore they may useful for the treatment of pathologic sequels of lipid peroxidation occurring in mammals, including man.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
NOVEL STEROIDS WITH PREGNANE SKELETON, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAMEThe invention relates to novel therapeutically active 21—aminosteroids of the formulawith pregnane skeleton, wherein two of X, Y and Z mean a nitrogen atom each and the third one is a methine group;R1 and R2 represent, independently from each other, a prim¬ ary amino group bearing as substituent a branched-chain C4_salkyl, —alkenyl or —alkynyl group, or a C^iocyclo- alkyl group comprising 1 to 3 ring(s) and being option¬ ally substituted by Cι_3al yl group(s) ; orR1 and R2 stand together for a spiro-heterocyclic secondary amino group containing at most 10 carbon atoms and optionally at least one oxygen atom as additional heteroatom; or one of R1 and R2 means an unsubstituted heterocyclic second¬ ary amino group containing 4 to 7 carbon atoms and the other one is an above-identified primary amino group,A4868-67 MR 

 an above-identified spiro-heterocyclic secondary amin group, or a heterocyclic secondary amino group con taining 4 to 7 carbon atoms and substituted by Cι_4 alkyl grou (s) ; and n is 1 or 2, as well as their acid addition salts and pharmaceutical com positions containing these compounds.Furthermore, the invention relates to a process for th preparation of the above compounds. The compounds of the formula (I) according to th invention are new and possess a valuable biological activ ity, mainly antioxidant (lipid peroxidation-inhibiting effect, when investigated under in vitro conditions. Som representatives of them show a remarkable effectivit in vivo on the cerebral trauma model.Accordingly, the invention relates also to a method o treatment which comprises administering a therapeuticall effective amount of a compound of the formula (I) or pharmaceutically acceptable acid addition salt thereof int the organism of a patient for inhibiting the peroxidation o lipids.Hereinafter and in the claims primary amino groups ar meant to contain a hydrogen atom as one substituent wherea the other substituent is a branched—chain C^g-^lkyl, —alke nyl or —alkynyl group, or a C4_*-Locycloalkyl group, compris ing 1 to 3 rings, and being optionally substituted by Cι_3 alkyl group(s) . The branched-chain C4_galkyl, —alkenyl an —alkynyl groups may be various iso—, sec— and tert—butyl butenyl, pentyl, pentenyl, pentynyl, hexyl, hexenyl, hexy nyl, pentyl, heptenyl, heptynyl, octyl, octenyl and octyny groups. Preferred representatives of these are the l,l-di methylethyl, 2,2-dimethylpropyl and
</DESCRIPTION>
<CLAIMS>
Claims :
1. Novel 21—aminosteroids of the formula
with pregnane skeleton, wherein two of X, Y and Z mean a nitrogen atom each and the thir one is a methine group; R
1
 and R
2
 represent, independently from each other, a prim ary amino group bearing as substituent a branched-chai C
4
_salkyl, —alkenyl or —alkynyl group, or a C4_ιocyclo alkyl group comprising 1 to 3 ring(s) and being option ally substituted by 


 group(s) ; or R
1
 and R
2
 stand together for a spiro-heterocyclic secondar amino group containing at most 10 carbon atoms an optionally at least one oxygen atom as additiona heteroatom; or one of R
1
 and R
2
 means an unsubstituted heterocyclic second ary amino group containing 4 to 7 carbon atoms and th other one is an above-identified primary amino group, an above-identified spiro-heterocyclic secondary amin group, or a heterocyclic secondary amino group con taining 4 to 7 carbon atoms and substituted by Cι_4 alkyl group(s); and n is 1 or 2, as well as acid addition salts thereof.
2. A compound selected from the group consisting of 


 21—{4-[2,4—bis(1,1-dimethylethylamino)—6-pyrimidiny1]- —l—piperazinyl}—16α—methylpregna—1,4,9(11)—triene—3,20- —dione,
21—{4-[2-bis(l,1—dimethylethylamino)—6-pyrrolidino-4- —pyrimidiny1]-l—piperazinyl}-16α-methylpregna-l,4,9(11)- —triene—3,20-dione,
21-{4-[2,4-bis(l—adamantylamino)—6—pyridinyl]-l-pi- peraziny1}—16α-methylpregna-1,4,9(11)-triene-3,20-dione,
21—{4-[2—(1—adamantylamino)—6—pyrrolidino—4- —pyrimidinyl]-l-piperazinyl}-16α-methylpregna-l,4 ,9(11)- —triene-3,20—dione,
21—{4-[2-bis(2,2-dimethylpropylamino)-6-pyrimidiny1]-l- —piperazinyl}-16α-methylpregna-l,4,9(11)—triene—3,20-dione,
21—{4-[2—(2,2-dimethylpropylamino)—6—pyrrolidino-4- -pyrimidiny1]-1-piperaziny1}-16α-methylpregna-1,4,9(11)- —triene-3,20-dione,
21-{4-[2,4—bis[ (4,4—dimethy1-1-penten—5-yl)amino]—6- —pyrimidinyl]
—l—piperazinyl}—16α—methylpregna—1,4,9(11)- —triene-3,20—dione, 21—{4-[2,4-bis(4,4—ethylenedioxy—1-piperidinyl)—6-
—pyrimidinyl]—l-piperazinyl}-16α-methylpregna-l,4,9(11)- —triene-3,20-dione,
16α-methyl-21-{4—[2-(2,2,6,6,-tetramethy1-1- piperidinyl)—6-pyrrolidino-4-pyrimidiny1]—l—piperazinyl}- pregna-1,4,9(11)-triene—3,20-dione,
16α—methy1-21—{4—[2-(1,1-dimethylethylamino)—4-(2,2- —dimethylpropylamino)—6—pyrimidinyl]—1—piperazinyl}pregna- —1,4,9(11)—triene-3,20—dione,
21-{4-[4,6-bis(1—adamantylamino)-2—pyrimidinyl]-l-pi- perazinyl}—16α—methylpregna-1,4,9(11)—triene—3,20-dione,
21—{4-[2,4-bis(cyclopentylamino)—6—pyrimidiny1-1-pi- perazinyl}—16α-methylpregna-l,4,9(ll)-triene-3,20-dione, as well as the acid addition salts of these compounds.
3. A pharmaceutical composition, which comprises as active ingredient a therapeutically effective amount of
21-aminosteroid of formula (I) having pregnane skeleton. 


wherein X, Y, Z, R
1
, R
2
 and n are as defined in claim 1 or a pharmaceutically acceptable acid addition salt thereof.
4. A process for the preparation of the novel 21—amino¬ steroids of the formula
having pregnane skeleton, wherein two of X, Y and Z mean a nitrogen atom each and the third one is a methine group; R***- and R
2
 represent, independently from each other, a prim- ary amino group bearing as substituent a branched-chain
C4_
8
alkyl, —alkenyl or —alkynyl group, or a C4_
10
cyclo- alkyl group comprising 1 to 3 ring(s) and being option¬ ally substituted by Cι_
3
alkyl group(s) ; or R
1
 and R
2
 stand together for a spiro-heterocyclic secondary amino group containing at most 10 carbon atoms and optionally at least one oxygen atom as additional heteroatom; or one of R
1
 and R
2
 means an unsubstituted heterocyclic second¬ ary amino group containing 4 to 7 carbon atoms and the other one is an above-identified primary amino group, an above-identified spiro-heterocyclic secondary amino group, or a heterocyclic secondary amino group con¬ taining 4 to 7 carbon atoms and substituted by Cι_4~ alkyl group(s); and n is l or 2, as well as acid addition salts thereof, which comprises 


 acylating 21-hydroxy—16α-methylpregna-l,4,9(ll)-triene- —3,20—dione with 4—bromobenzenesulfonyl chloride or 4—nitro¬ benzenesulfonyl chloride, respectively, then reacting the obtained 21—substituted pregnane deriva- i tive of the formula

 wherein R stands for 4—bromobenzenesulfonyl or 4—nitrobenze¬ nesulfonyl group, with a piperazinyl—bis(alkylamino)pyrimi- dine derivative of the formula
wherein X, Y, Z, R
1
, R
2
 and n are as defined above, and, if desired, liberating an obtained pregnane derivative of the formula (I) , wherein X, Y, Z, R , R
2
 and n are as defined above, from a salt and/or, if desired, trans¬ forming an obtained free base to an acid addition salt by reacting it with an appropriate acid.
5. A process as claimed in claim 4, which comprises reacting 21-hydroxy—16α-methylpregna-1,4,9(ll)-triene-3,20- dione with 4—bromobenzenesulfonyl chloride or 4—nitrobenze¬ nesulfonyl chloride, respectively, in an ether type solvent in the presence of a tertiary amine base at room tempera¬ ture. 6. A process as claimed in claim 4, which comprises reacting 21-(nitrobenzenesulfonyloxy)-16α-methylpregna- 


—1,4,9(ll)-triene—3,20-dione with a piperazinyl—bis(alkyl amino)pyrimidine derivatives of the formula (III) , wherei X, Y, Z, R
1
, R
2
 and n are as claimed in defined 4, in polar solvent such as a 0
3
-5 aliphatic ketone, suitabl acetone, or a C2_4 aliphatic ketone, suitably acetone, or C
2
_4 aliphatic nitrile, suitably acetonitrile, in the pres ence of a solid-phase acid binding agent, preferabl potassium carbonate, at a temperature of 55 to 70°C.
7. Method for inhibiting the peroxidation of lipids characterized by administering to a patient to be treated therapeutically effective amount of a 21—aminosteroi derivative of the formula (I) having pregnane skeleton wherein X, Y, Z, R
1
, R
2
 and n are as defined in claim 4, o a pharmaceutically acceptable acid addition salt thereo alone or in the form of a pharmaceutical composition. 

</CLAIMS>
</TEXT>
</DOC>
